Xvivo Perfusion (Sweden) Insiders
| XVIVO Stock | SEK 451.50 5.50 1.23% |
Xvivo Perfusion employs about 133 people. The company is managed by 10 executives with a total tenure of roughly 26 years, averaging almost 2.0 years of service per executive, having 13.3 employees per reported executive. Breaking down Xvivo Perfusion's management performance can provide insight into the firm performance.
| Magnus Nilsson CEO CEO and Director |
Xvivo |
Xvivo Perfusion Management Team Effectiveness
Xvivo Perfusion's management efficiency ratios could be used to measure how well Xvivo Perfusion manages its routine affairs as well as how well it operates its assets and liabilities.Xvivo Perfusion Workforce Comparison
Xvivo Perfusion AB is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,399. Xvivo Perfusion holds roughly 133 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.04 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.04 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.04. Xvivo Perfusion AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Xvivo Perfusion AB Price Series Summation is a cross summation of Xvivo Perfusion price series and its benchmark/peer.
Xvivo Perfusion Notable Stakeholders
A Xvivo Perfusion stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xvivo Perfusion often face trade-offs trying to please all of them. Xvivo Perfusion's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xvivo Perfusion's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Magnus Nilsson | CEO and Director | Profile | |
| Christer Flon | Global Head of Marketing and Sales and Global Marketing and Sales Director | Profile | |
| Jaya Tiwari | VP Affairs | Profile | |
| Katrin Gisselfalt | Global Director | Profile | |
| Charlotte Walldal | Global director | Profile | |
| Lena BSc | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Johan Holmstrom | Chief Officer | Profile | |
| Christoffer Rosenblad | Acting Officer | Profile | |
| Kristoffer Nordstrom | CFO Relations | Profile |
About Xvivo Perfusion Management Performance
The success or failure of an entity such as Xvivo Perfusion AB often depends on how effective the management is. Xvivo Perfusion management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xvivo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xvivo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Xvivo Perfusion AB , a medical technology company, provides solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. Xvivo Perfusion AB was founded in 1998 and is headquartered in Gothenburg, Sweden. Xvivo Perfusion operates under Medical Devices classification in Sweden and is traded on Stockholm Stock Exchange. It employs 45 people.
Please note, the imprecision that can be found in Xvivo Perfusion's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xvivo Perfusion AB. Check Xvivo Perfusion's Beneish M Score to see the likelihood of Xvivo Perfusion's management manipulating its earnings.
Xvivo Perfusion Workforce Analysis
Traditionally, organizations such as Xvivo Perfusion use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xvivo Perfusion within its industry.Xvivo Perfusion Manpower Efficiency
Return on Xvivo Perfusion Manpower
| Revenue Per Employee | 1.9M | |
| Revenue Per Executive | 25.8M | |
| Net Income Per Employee | 61.3K | |
| Net Income Per Executive | 815.2K | |
| Working Capital Per Employee | 609K | |
| Working Capital Per Executive | 8.1M |
Additional Tools for Xvivo Stock Analysis
When running Xvivo Perfusion's price analysis, check to measure Xvivo Perfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xvivo Perfusion is operating at the current time. Most of Xvivo Perfusion's value examination focuses on studying past and present price action to predict the probability of Xvivo Perfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xvivo Perfusion's price. Additionally, you may evaluate how the addition of Xvivo Perfusion to your portfolios can decrease your overall portfolio volatility.